CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members
- PMID: 12917689
- DOI: 10.1038/nature01803
CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members
Abstract
Familial cylindromatosis is an autosomal dominant predisposition to tumours of skin appendages called cylindromas. Familial cylindromatosis is caused by mutations in a gene encoding the CYLD protein of previously unknown function. Here we show that CYLD is a deubiquitinating enzyme that negatively regulates activation of the transcription factor NF-kappaB by specific tumour-necrosis factor receptors (TNFRs). Loss of the deubiquitinating activity of CYLD correlates with tumorigenesis. CYLD inhibits activation of NF-kappaB by the TNFR family members CD40, XEDAR and EDAR in a manner that depends on the deubiquitinating activity of CYLD. Downregulation of CYLD by RNA-mediated interference augments both basal and CD40-mediated activation of NF-kappaB. The inhibition of NF-kappaB activation by CYLD is mediated, at least in part, by the deubiquitination and inactivation of TNFR-associated factor 2 (TRAF2) and, to a lesser extent, TRAF6. These results indicate that CYLD is a negative regulator of the cytokine-mediated activation of NF-kappaB that is required for appropriate cellular homeostasis of skin appendages.
Comment in
-
Signal transduction: aspirin, ubiquitin and cancer.Nature. 2003 Aug 14;424(6950):738-9. doi: 10.1038/424738a. Nature. 2003. PMID: 12917671 No abstract available.
Similar articles
-
The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.Nature. 2003 Aug 14;424(6950):801-5. doi: 10.1038/nature01802. Nature. 2003. PMID: 12917691
-
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB.Nature. 2003 Aug 14;424(6950):797-801. doi: 10.1038/nature01811. Nature. 2003. PMID: 12917690
-
NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway.J Biol Chem. 2004 Aug 27;279(35):36171-4. doi: 10.1074/jbc.M406638200. Epub 2004 Jun 28. J Biol Chem. 2004. PMID: 15226292
-
CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.Cell Death Differ. 2010 Jan;17(1):25-34. doi: 10.1038/cdd.2009.43. Cell Death Differ. 2010. PMID: 19373246 Free PMC article. Review.
-
[Research progress of deubiquitinating enzyme CYLD to regulate liver-related diseases].Zhonghua Gan Zang Bing Za Zhi. 2019 Jun 20;27(6):477-480. doi: 10.3760/cma.j.issn.1007-3418.2019.06.019. Zhonghua Gan Zang Bing Za Zhi. 2019. PMID: 31357769 Review. Chinese.
Cited by
-
Signaling mechanisms regulating B-lymphocyte activation and tolerance.J Mol Med (Berl). 2015 Feb;93(2):143-58. doi: 10.1007/s00109-015-1252-8. Epub 2015 Jan 29. J Mol Med (Berl). 2015. PMID: 25627575 Review.
-
The relationship between TRAF6 and tumors.Cancer Cell Int. 2020 Sep 3;20:429. doi: 10.1186/s12935-020-01517-z. eCollection 2020. Cancer Cell Int. 2020. PMID: 32905356 Free PMC article. Review.
-
Caspase-8 in inflammatory diseases: a potential therapeutic target.Cell Mol Biol Lett. 2024 Oct 8;29(1):130. doi: 10.1186/s11658-024-00646-x. Cell Mol Biol Lett. 2024. PMID: 39379817 Free PMC article. Review.
-
CYLD and the NEMO Zinc Finger Regulate Tumor Necrosis Factor Signaling and Early Embryogenesis.J Biol Chem. 2015 Sep 4;290(36):22076-84. doi: 10.1074/jbc.M115.658096. Epub 2015 Jul 29. J Biol Chem. 2015. PMID: 26224629 Free PMC article.
-
The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP/TAZ and TGF Signaling.Cancers (Basel). 2020 Jul 24;12(8):2047. doi: 10.3390/cancers12082047. Cancers (Basel). 2020. PMID: 32722292 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous